Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
- PMID: 32010587
- PMCID: PMC6976346
- DOI: 10.21037/tlcr.2019.10.17
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Abstract
There were many clinical studies on lung cancer in 2018. In particular, significant progress has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have shown good results. For patients with specific gene mutations, the new generation inhibitors also showed good results in clinical trials. In this review, we summarize the clinical trials in lung cancer in 2018 and describe the progress and prospects for lung cancer therapies.
Keywords: Non-small cell lung cancer (NSCLC); clinical trails; immunotherapy; small cell lung cancer (SCLC); targeted therapy.
2019 Translational Lung Cancer Research. All rights reserved.
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
References
-
- Pirker R, Buder A, Filipits M. Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3. Transl Cancer Res 2017;6:S265-9. 10.21037/tcr.2017.03.12 - DOI
Publication types
LinkOut - more resources
Full Text Sources